NeuroSense Therapeutics Ltd. Nasdaq Nrsn NeuroSense or the Company , a late-stage clinical biotechnology company developing treatments for neurodegenerative diseases, today announced plans to incorporate newly generated
Why Is NRSNW (NRSNW) Stock Down Today?
Updated Nov 22, 2026 7:56 AM ET ยท Prev Close $0.01
Session Regime & Catalyst Assessment
68% Signal ConvictionNrsnw Pulling Back 10.91% on 1.39x Relative Volume
Nrsnw (Nrsnw) is pulling back 10.91% (+$0.00) to $0.00 on 1.39x average session volume. Relative to benchmarks, NRSNW is lagging the S&P 500 by -7.27%.
NeuroSense Therapeutics Ltd. Nasdaq Nrsn NeuroSense or the Company , a late-stage clinical biotechnology company developing treatments for neurodegenerative diseases, today announced plans to incorporate newly generated
Market & Sector Relative Strength
NRSNW lagging the S&P 500 by -7.27%Recent NRSNW Catalyst Headlines
Verified WireNeuroSense Therapeutics Ltd. Nasdaq Nrsn NeuroSense or the Company , a biotechnology company developing treatments for neurodegenerative diseases, today announced that its clinical and biomarker findings informing the ne
NeuroSense Therapeutics Ltd. Nasdaq Nrsn NeuroSense or the Company , a late-stage clinical biotechnology company developing treatments for neurodegenerative diseases, today announced that it has filed a patent applicatio
NeuroSense Therapeutics Ltd. Nasdaq Nrsn NeuroSense or the Company , a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that its
1โ3 Day Expected Range & Key Level
54% Follow-ThroughAbout NRSNW
Get Instant NRSNW Catalyst Alerts
Receive an email alert when NRSNW triggers an unusual volume breakout, options sweep, or rating shift.
NRSNW Session & Catalyst FAQ
Why is NRSNW stock down today?
Nrsnw (Nrsnw) is pulling back 10.91% (+$0.00) to $0.00 on 1.39x average session volume. Relative to benchmarks, NRSNW is lagging the S&P 500 by -7.27%.
Is NRSNW stock a buy or sell right now?
Today's session carries a 68% catalyst conviction score on 1.39x relative volume (moderate participation). Our multi-factor model currently rates NRSNW as AVOID NEW MONEY. Review full valuation, quality, and timing signals on the NRSNW Buy or Sell Decision Brief โ
What is NRSNW's intrinsic value and expected trading range?
At $0.00, NRSNW's modeled 1-to-3 session range is $0.00 โ $0.00. Compare current price against multi-year cash flow projections in the NRSNW Intrinsic Value & DCF Model โ and Market Cycle Phase Tracker โ
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.